---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-016400"
form_type: "8-K"
ticker: "SKYE"
cik: "0001516551"
company_name: "Skye Bioscience, Inc."
filed_at: "2026-03-10T23:59:59+00:00"
generated_at: "2026-05-15T16:32:17.740065+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Skye reports Q4 loss $14.4M, cash $25.7M; initiates higher-dose CBeyond study after 22.3% weight loss at 52 weeks

## Summary
- Net loss Q4 2025: $14.4M; full year $55.9M; cash & equivalents $25.7M as of Dec 31, 2025.
- Interim 52-week data: nimacimab+semaglutide achieved 22.3% mean weight loss; no plateau observed.
- Initiated CBeyond Expansion Study: higher doses (400 mg and 600 mg IV) vs placebo; topline Q4 2026.
- Weight regain during 13-week off-treatment: combo cohort regained 17.8% vs 37.3% for semaglutide alone.
- FDA Type C meeting completed; feedback informing Phase 2b design including potential add-on with incretin.

## SEC filing metadata
- accession: 0001628280-26-016400
- form_type: 8-K
- ticker: SKYE
- cik: 0001516551
- company_name: Skye Bioscience, Inc.
- filed_at: 2026-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1516551/000162828026016400/0001628280-26-016400-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1516551/000162828026016400/skye-20260310.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-016400
- JSON: https://secwatch.observer/filing/0001628280-26-016400.json
- Plain text: https://secwatch.observer/filing/0001628280-26-016400.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.